AstraZeneca Balance Sheet
NYSE: AZNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AstraZeneca financial position
At the end of fiscal 2025, AstraZeneca reported total assets of $114.07 billion, up 9.6% from a year earlier against total liabilities of $65.36 billion. Shareholders' equity stood at $48.67 billion, or 42.7% of assets. The company held $5.71 billion in cash and equivalents against $27.82 billion of debt, a net debt position of $22.11 billion.
The current ratio (current assets divided by current liabilities) was 0.94, meaning short-term obligations exceed short-term assets. Debt-to-equity was 0.57.
Summary generated from market data by MetaCap's automated system. Methodology
AstraZeneca balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 5.71B | 5.49B | 5.84B | 6.17B | 6.33B | 7.83B | 5.37B | 4.83B | 3.32B | 5.02B |
| Short-Term Investments | 30.00M | 166.00M | 122.00M | 239.00M | 69.00M | 160.00M | 849.00M | 849.00M | 1.23B | 884.00M |
| Receivables | 15.18B | 12.97B | 12.13B | 10.52B | 9.64B | 7.02B | 5.76B | 5.57B | 5.01B | 4.57B |
| Inventory | 6.56B | 5.29B | 5.42B | 4.70B | 8.98B | 4.02B | 3.19B | 2.89B | 3.04B | 2.33B |
| Total Current Assets | 28.72B | 25.83B | 25.05B | 22.59B | 26.24B | 19.54B | 15.56B | 15.59B | 13.15B | 13.26B |
| Property, Plant & Equipment | 12.96B | 10.25B | 9.40B | 8.51B | 9.18B | 8.25B | 7.69B | 7.42B | 7.62B | 6.85B |
| Goodwill | 21.24B | 21.02B | 20.05B | 19.82B | 20.00B | 11.85B | 11.67B | 11.71B | 11.82B | 11.66B |
| Intangible Assets | 37.85B | 37.18B | 38.09B | 39.31B | 42.49B | 20.95B | 20.83B | 21.96B | 26.19B | 27.59B |
| Total Assets | 114.07B | 104.03B | 101.12B | 96.48B | 105.36B | 66.73B | 61.38B | 60.65B | 63.35B | 62.53B |
| Accounts Payable | 25.28B | 22.46B | 22.37B | 19.04B | 18.94B | 15.79B | 13.99B | 12.84B | 11.64B | 10.49B |
| Short-Term Debt | 3.10B | 2.34B | 5.13B | 5.31B | 1.66B | 2.19B | 1.82B | 1.75B | 2.25B | 2.31B |
| Total Current Liabilities | 30.62B | 27.87B | 30.54B | 26.29B | 22.59B | 20.31B | 18.12B | 16.29B | 16.38B | 15.26B |
| Long-Term Debt | 24.71B | 26.51B | 22.36B | 22.96B | 28.13B | 17.50B | 15.73B | 17.36B | 15.56B | 14.50B |
| Total Liabilities | 65.36B | 63.16B | 61.95B | 59.42B | 66.08B | 51.09B | 46.78B | 46.61B | 46.71B | 45.86B |
| Shareholders' Equity | 48.67B | 40.79B | 39.14B | 37.04B | 39.27B | 15.62B | 13.13B | 12.47B | 14.96B | 14.85B |
| Retained Earnings | 10.97B | 3.16B | 1.50B | -574.00M | 1.71B | 5.30B | 2.81B | 5.68B | 8.22B | 8.14B |
| Total Debt | 27.82B | 28.84B | 27.49B | 28.28B | 29.79B | 19.70B | 17.55B | 19.11B | 17.81B | 16.81B |
| Net Cash (Debt) | -22.08B | -23.19B | -21.53B | -21.87B | -23.40B | -11.71B | -11.33B | -13.43B | -13.25B | -10.91B |
This table shows 10 annual periods of AstraZeneca's balance sheet, from FY 2025 back to FY 2016, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow AZN's reporting calendar. What is a balance sheet?